New drug for congenital Factor VII deficiency
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new drug called Sutacimig for people with congenital Factor VII deficiency, a rare bleeding disorder. The drug is designed to help prevent or control bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have confirmed Factor VII deficiency with an activity level below 10% (measured at least twice).
- You have a history of severe bleeding or have needed treatment with Factor VII or fresh frozen plasma for a bleed.
- You do not have inhibitors (antibodies) to Factor VII.
- You have not had a blood clot (such as a deep vein thrombosis or pulmonary embolism).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new injection called SR604 in people with congenital factor VII deficiency, a rare bleeding disorder. The study will check if the drug is safe and effective at preventing or treating bleeding episodes.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This trial tests a new factor VIII treatment (SKP-0141) for severe hemophilia A. It aims to see if it can prevent or treat bleeding episodes, replacing standard factor VIII therapy.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.
Hear when a new Congenital Factor VII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.